• SP600125: A JNK–Nrf2 Assay Strategy

  2026-09-05

  SP600125 is a JNK inhibitor suited to dissecting how kinase activity intersects with redox stress and Nrf2 loss. This guide develops a time-resolved assay framework grounded in rotavirus research, with practical guidance for inflammation, apoptosis, and cytokine studies.

• V5 Epitope Tag Peptide: Binding-Aware Workflows

  2026-09-04

  The V5 Epitope Tag Peptide supports rigorous protein detection by linking sequence-level identity with antibody-binding behavior. This article explains how epitope accessibility, assay kinetics, and peptide controls improve Western blotting, immunoprecipitation, and advanced imaging decisions.

• Cyclophosphamide: Reliable Cytotoxicity Assays

  2026-09-04

  Learn how Cyclophosphamide SKU A2343 can address variable cytotoxicity, apoptosis, and proliferation assay results through mechanism-aware design, controlled formulation, and documented quality control. This scenario-based guide covers exposure selection, vehicle compatibility, data interpretation, and practical vendor evaluation.

• PPM-18 Workflow for iNOS and NF-κB Studies

  2026-09-03

  PPM-18 enables pathway-focused studies of iNOS expression, NF-κB activation, and inflammatory mediator release without directly targeting constitutive NOS enzymes. This guide translates its chemistry and mechanism into reproducible macrophage, sepsis research, and bone-inflammation workflows while emphasizing solvent control, orthogonal readouts, and practical troubleshooting.

• Candida krusei Apoptosis in Bovine Mammary Cells

  2026-09-03

  The reference study shows that the yeast and hypha phases of Candida krusei trigger bovine mammary epithelial cell apoptosis through different signaling routes. Its phase-resolved co-culture design connects fungal morphology with mitochondrial or death ligand/receptor mechanisms and provides a framework for testing caspase involvement in fungal mastitis research.

• Fenipentol: From Chuanxiong Chemistry to Translation

  2026-09-02

  Fenipentol, also known as 1-Phenyl-1-pentanol, offers a distinctive translational research opportunity at the intersection of Chuanxiong natural-product chemistry, estrogen receptor α signaling, and gastrointestinal secretion biology. This article examines the evidence, experimental priorities, safety context, and strategic path toward validating Fenipentol as a research tool for hepatobiliary, pancreatic, and cardiovascular investigations.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-02

  The reference commentary highlights a placebo-controlled phase 3 evaluation of oral mavorixafor, a selective CXCR4 antagonist, in patients with WHIM syndrome. By increasing the duration of neutrophil and lymphocyte recovery and reducing infections, the study supports mechanism-directed treatment for this rare immunodeficiency while leaving important questions about lifelong safety and disease modification unresolved.

• Ciprofloxacin Hydrochloride: Designing Better Assays

  2026-09-01

  Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic with a well-defined DNA-targeting mechanism and broader research utility. This guide presents an evidence-aware framework for separating antibacterial activity from host-cell, immunomodulatory, and exploratory antiparasitic signals.

• Carbapenemase Gene Transfer in CREC

  2026-09-01

  Chen et al. integrate resistance-gene localization, conjugation testing, mobile-element analysis, and strain genotyping to clarify how carbapenemase-encoding genes circulate among carbapenem-resistant Enterobacter cloacae in Guangdong hospitals. The study identifies plasmid-associated blaNDM-1 and efficient laboratory transfer as major surveillance concerns, while also showing why local susceptibility testing and infection-control investigations must accompany molecular detection.

• Oxaliplatin Resistance and PARP Inhibition in Gastric Cancer

  2026-08-31

  This reference study links Oxaliplatin resistance in gastric cancer to PARP1 activity and identifies compromised CDK1 activity as a potential vulnerability in BRCA-proficient tumors. Across patient-derived organoids, resistant cell models, and xenografts, the findings support combining Oxaliplatin with olaparib as a preclinical strategy for overcoming treatment resistance.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-31

  A 2025 study shows that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to AXL, ACE2, and NRP1 in peptide-dependent patterns. Its structure–activity analysis identifies peptide truncation and modification at tyrosine 4 as important determinants, while also highlighting the need to distinguish receptor-binding effects from demonstrated viral infection.

• FLAG tag Peptide: Exosome Assay Workflows

  2026-08-30

  Use the FLAG tag Peptide (DYKDDDDK) to build gentle, traceable purification and detection workflows for recombinant proteins, including mechanistic studies of exosome biology. Its peptide-based competition strategy helps preserve protein complexes while exposing limitations such as poor elution of 3X FLAG constructs.

• Clozapine as a Translational Map of Brain-Safety Biology

  2026-08-29

  Clozapine offers translational researchers more than a benchmark atypical antipsychotic medication: it connects polypharmacology, prefrontal ERK1/2 signaling activation, EGF receptor mediated signaling, behavioral models, and safety-oriented hepatotoxicity studies. This article presents a hypothesis-driven framework for using Clozapine to relate receptor engagement to circuit biology while keeping magnetic stimulation findings, pharmacology, and liver-risk data analytically distinct.

• WAY-100635 for 5-HT1A Mechanism Studies

  2026-08-28

  WAY-100635 is a high-affinity, silent 5-HT1A antagonist for separating receptor-mediated effects from broader serotonergic, cannabinoid, and behavioral signals. This workflow connects radioligand binding and functional assays with pain, affective-behavior, and imaging applications while emphasizing solvent control, assay validation, and interpretation limits.

• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-08-28

  Protect intact cellular and tissue proteins during OXPHOS, Western blot, Co-IP, and kinase workflows with an EDTA-free, broad-spectrum inhibitor format. This practical guide connects sample-preservation choices to the LRPPRC–dasatinib dual-genome OXPHOS study and provides executable starting conditions for extraction and troubleshooting.

8588 records 1/573 page Next 12345 下5页 Last page